Biosimilar agents in oncology/haematology: from approval to practice - Wikidata - awgldk - TriplyDB

Biosimilar agents in oncology/haematology: from approval to practice

Biosimilar agents in oncology/haematology: from approval to practice

http://www.wikidata.org/entity/Q34892411

about

The emergence of biosimilar insulin preparations--a cause for concern?Expert perspectives on biosimilar monoclonal antibodies in breast cancer Review article: biosimilars are the next generation of drugs for liver and gastrointestinal diseases Regulatory considerations in oncologic biosimilar drug development Clinical considerations for biosimilar antibodies.Biosimilars: Implications for health-system pharmacists.A randomized, non-inferiority study comparing efficacy and safety of a single dose of pegfilgrastim versus daily filgrastim in pediatric patients after autologous peripheral blood stem cell transplant Recombinant glucagon: a differential biological activity.Regulatory and clinical considerations for biosimilar oncology drugs Herpes murine model as a biological assay to test dialyzable leukocyte extracts activity.Switching Between Epoetins: A Practice in Support of Biosimilar Use.Safety and efficacy of granulocyte colony-stimulating factor biosimilars in engraftment after autologous stem cell transplantation for haematological malignancies: a 4-year, single institute experience with different conditioning regimens Doctors commitment and long-term effectiveness for cost containment policies: lesson learned from biosimilar drugs.Assessing gastroenterologist and patient acceptance of biosimilars in ulcerative colitis and Crohn's disease across Germany Mobilization of PBSC for allogeneic transplantation by the use of the G-CSF biosimilar XM02 in healthy donors.Comparison of originator and biosimilar therapeutic monoclonal antibodies using comprehensive two-dimensional liquid chromatography coupled with time-of-flight mass spectrometry.Erythropoietin biosimilars currently available in hematology-oncology.Optimized granulocyte colony-stimulating factor prophylaxis in adult cancer patients: from biological principles to clinical guidelines.Biosimilar recombinant human erythropoietins ("epoetins") and future erythropoiesis-stimulating treatments.The safety of switching between therapeutic proteins.Epoetin biosimilars in Europe: five years on.Pharmacovigilance and biosimilars: considerations, needs and challenges.Clinical experience with Zarzio® in Europe: what have we learned?Biosimilar G-CSF based mobilization of peripheral blood hematopoietic stem cells for autologous and allogeneic stem cell transplantation Long-active granulocyte colony-stimulating factor for peripheral blood hematopoietic progenitor cell mobilization.Biosimilars: Hope and concern.Current Status of Biosimilars in Oncology.Is there a reason for concern or is it just hype? - A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars.Tbo-Filgrastim: A Review in Neutropenic Conditions.Interchangeability among reference insulin analogues and their biosimilars: regulatory framework, study design and clinical implications.Assessing physician and patient acceptance of infliximab biosimilars in rheumatoid arthritis, ankylosing spondyloarthritis and psoriatic arthritis across Germany.Evaluation of a biosimilar granulocyte colony-stimulating factor (filgrastim XM02) for peripheral blood stem cell mobilization and transplantation: a single center experience in Japan.Cost savings from anemia management with biosimilar epoetin alfa and increased access to targeted antineoplastic treatment: a simulation for the EU G5 countries.Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation.Anti-neoplastic biosimilars--the same rules as for cytotoxic generics cannot be applied.Biosimilar rhG-CSFs: how similar are they?Improving Access to Cancer Treatments: The Role of Biosimilars.The Concept of Biosimilars: From Characterization to Evolution-A Narrative Review.A comparative analysis of biosimilar vs. originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma: a propensity-score weighted multicenter approach.A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer.

P2860

Q26824362-19AFD2E4-7E80-4E69-B434-D1EE52994AB7 Q26865410-3CC228B8-5A5D-4E55-BEC0-EBD738234148 Q27013577-476A123E-D5F3-4D4E-B05A-398E47C5A569 Q27027947-DFFBEF9D-BD88-4797-AD43-DA3AFB704BBF Q30377239-D634043D-069E-4211-B62F-6B3A738F651B Q34372394-D4B9E113-95A0-4CD6-A276-9E3C1DFE45F6 Q34544831-3DAFA451-1EC3-4AA3-8C2F-B0C395E673DB Q35266434-3BC8F4EF-DB86-42BB-9193-9936989FD227 Q35505833-41B2CF0F-5065-4077-901D-1F629BBA0085 Q35578777-A61FEDA1-623B-40D1-9A0F-AF80043E0B02 Q35884615-3BB4F48E-A45A-4D20-A221-8B4E377FF530 Q36187379-9362FF00-7665-4E8C-B0CE-47ED944DF3AD Q36284094-606CEBD8-62A8-4725-AC49-7BA7DC59BCE5 Q36347183-EBC31BF9-70EF-4AC8-9222-846F3FE7AA1F Q36981948-D3B91075-EACB-4DCA-89C6-06ACFDD114E1 Q37327298-10097E47-E8A4-4D76-83A7-D10554342F43 Q37976605-A79CBA66-C63D-4777-8C21-4375CF260851 Q37996443-9683AFCF-D2F8-4FB7-9E7C-7333AFD60F74 Q37999380-828829F0-8764-4AE9-969D-395047476818 Q38030980-2158E2E5-F8E3-4193-99D3-8F6041EDA2C6 Q38067654-95F32C2D-DED1-4ED4-8DBC-87160071F155 Q38092850-824FC2F0-58EE-4FD1-B514-9B2D73C92E2F Q38125609-0A7BA33F-8815-4CD8-A677-1E83439CAE97 Q38186025-C37A4C8E-8EF2-4267-A4D3-6DC19F5137A3 Q38193590-B084FA99-BC92-4048-889F-7A90D314BE88 Q38590668-384F909A-6CB8-4C74-BF29-F2B8C904E2B8 Q38687093-D87BB446-1476-4094-9D3D-3EC28E4AB359 Q38708927-F148574F-EDA6-471E-8EF7-AC7834C02408 Q38792513-78D26063-762D-4108-9521-4B984B4541B8 Q38812953-8B8BDF4B-1014-4441-B2D4-C33C9874E219 Q38885209-339EE93E-AE81-4BE2-A052-2F2FD3B58B72 Q38969947-282ACB2F-1A54-44CF-8ED0-D09B2730A611 Q39141802-329FB3D8-A759-4B29-A3C7-93848F76BA2E Q42783302-38D3EB7C-F6CC-4C16-A39D-0818ED45ECA0 Q44638976-B09E3563-F99C-450E-B385-F722D45C3858 Q45788056-A7689347-ACB8-4F1C-958A-E03C65183DE3 Q47099597-99999279-6B0B-4496-82AF-D886471F15EF Q47760510-0CF486B7-2750-4703-8EA3-7228E2BDE11F Q48281446-94A90099-086F-469C-97DF-7432E609F35B Q50990877-F764338C-540F-42A9-9A43-33CC4628550D

P2860

Biosimilar agents in oncology/haematology: from approval to practice

http://www.wikidata.org/entity/Q34892411

description

2011 nî lūn-bûn

@nan

2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Biosimilar agents in oncology/haematology: from approval to practice

@ast

Biosimilar agents in oncology/haematology: from approval to practice

@en

Biosimilar agents in oncology/haematology: from approval to practice

@nl

type

label

Biosimilar agents in oncology/haematology: from approval to practice

@ast

Biosimilar agents in oncology/haematology: from approval to practice

@en

Biosimilar agents in oncology/haematology: from approval to practice

@nl

prefLabel

Biosimilar agents in oncology/haematology: from approval to practice

@ast

Biosimilar agents in oncology/haematology: from approval to practice

@en

Biosimilar agents in oncology/haematology: from approval to practice

@nl

P1433

Q34892411-4BAC5B48-AFC6-458E-98DB-5899471A96C9

P1476

Q34892411-3770A465-2394-44C7-80D4-22B2BD12A8C3

P2093

Q34892411-750B3C32-EDD5-4362-9263-54A2F459B79F

Q34892411-8A5047ED-0923-4636-87B5-D94B4DE458B5

P275

Q34892411-25851F71-48A7-45FE-9FA0-10AAE9331266

P2860

Q34892411-083E5124-2444-4B9E-89C7-DDBFEFC371BF

Q34892411-2F5DA4C8-7DC2-490B-98AB-4B15447D538E

Q34892411-5A8E011D-4E01-4D34-A425-93441743B5BF

Q34892411-62475026-01C6-4744-A3BB-55869FBD7070

Q34892411-89C51A92-B9B0-43D8-B011-6D9658C34902

Q34892411-97EB5BE4-497E-4EBC-8F9E-CD8AEB7B8FB1

Q34892411-A40EFB8D-2F54-409A-A2C9-88ACC7E2FEB4

Q34892411-DA8A5DCC-7DD0-477C-AF99-22772902AEFB

Q34892411-E07FC8F9-8717-4F68-9F3A-E4FFAA72F7CB

Q34892411-F1C272DB-F32D-4E53-B8AF-013FA2B64170

P304

Q34892411-7FB88D18-443E-45EF-8597-EC4337FDF972

P31

Q34892411-5EE1E756-1C0B-4BEC-8D3A-452B1BB03321

Q34892411-90E12470-ADAF-4885-9A0A-E08241982216

P356

Q34892411-8EC0D54C-B092-4F7E-B84A-EBAC7AC18062

P433

Q34892411-3D1ABD5D-68D2-44F9-9BB1-BC4839B1EA89

P478

Q34892411-6DDC5E4C-FCB8-43EA-9FA6-C4E4AD6237F0

P577

Q34892411-31098688-C393-4453-8783-F390504FDAF4

Q34892411-3B864CEA-64BB-4A4F-9200-99E9F7F64D94

P5875

Q34892411-8074059C-9A0B-405B-B572-E9A81E4A1846

P698

Q34892411-813F986F-21FB-4D0B-A0B1-4E684487CB77

P921

Q34892411-73B91A56-F7E1-4614-B30E-F402045D80FB

P932

Q34892411-3372D3D5-8F88-4DE9-9B62-E9BCD3965C46

P356

J.1600-0609.2010.01566.X

P1433

European Journal of Haematology

P1476

Biosimilar agents in oncology/haematology: from approval to practice

@en

P2093

Dietger Niederwieser

http://www.w3.org/2001/XMLSchema#string

Stephan Schmitz

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 2.5 Unported

P2860

Comparative testing and pharmacovigilance of biosimilars.

A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia.

Follow-on biologics: challenges of the "next generation".

EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours.

The protein science of biosimilars.

Immunogenicity of biopharmaceuticals.

The challenge of biosimilars.

Biotherapeutics in the era of biosimilars: what really matters is patient safety.

The first biosimilar epoetin: but how similar is it?

Assessing the bioequivalence of biosimilars The Retacrit case.

P304

277-288

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1600-0609.2010.01566.X

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

86

http://www.w3.org/2001/XMLSchema#string

P577

2011-01-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2011-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49700124

http://www.w3.org/2001/XMLSchema#string

P698

21175852

http://www.w3.org/2001/XMLSchema#string

P921

biomedical investigative technique

P932

3085072

http://www.w3.org/2001/XMLSchema#string